Author:Arvid Söderhäll

Empros Pharma participates in Bio Korea

CEO Arvid Söderhäll participated in at the Bio-Korea conference in Seoul in May. South Korea represents a vibrant region with an impressive traction. Empros Pharma has established contacts with investors, pharmaceutical industry, key opinion leaders, regulatory authority as well as consultants....

0
3

Pressrelease Phase 2a trial

Swedish Start-Up Pharma reveals positive Phase 2a trial - results from a novel oral medication treatment of obesity  The Swedish Pharmaceutical start-up Empros Pharma AB has new clinical results from a Phase 2a trial of its first novel and unique product EMP16; an oral drug for...

0
1

Phase 2a trial concluded

Medical background of Empros first product The prevalence of overweight and obesity is increasing worldwide. In 2015, it was estimated that about 108 million children and 604 million adults were obese worldwide. The overall prevalence of obesity was 5.0% among children and 12.0% among adults. Among...

0
0